314 related articles for article (PubMed ID: 10552997)
1. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
Mahley RW; Huang Y; Rall SC
J Lipid Res; 1999 Nov; 40(11):1933-49. PubMed ID: 10552997
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
3. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
6. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
Ji ZS; Fazio S; Mahley RW
J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
Huang Y; Schwendner SW; Rall SC; Sanan DA; Mahley RW
J Biol Chem; 1997 Sep; 272(36):22685-94. PubMed ID: 9312550
[TBL] [Abstract][Full Text] [Related]
9. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
[TBL] [Abstract][Full Text] [Related]
10. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2.
Huang Y; Schwendner SW; Rall SC; Mahley RW
J Biol Chem; 1996 Nov; 271(46):29146-51. PubMed ID: 8910571
[TBL] [Abstract][Full Text] [Related]
11. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
[TBL] [Abstract][Full Text] [Related]
12. Contribution of
Bea AM; Larrea-Sebal A; Marco-Benedi V; Uribe KB; Galicia-Garcia U; Lamiquiz-Moneo I; Laclaustra M; Moreno-Franco B; Fernandez-Corredoira P; Olmos S; Civeira F; Martin C; Cenarro A
Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
[TBL] [Abstract][Full Text] [Related]
13. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
[TBL] [Abstract][Full Text] [Related]
14. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
Smelt AH; de Beer F
Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
[TBL] [Abstract][Full Text] [Related]
16. The role of apolipoprotein E genetic variants in lipoprotein disorders.
Rall SC; Mahley RW
J Intern Med; 1992 Jun; 231(6):653-9. PubMed ID: 1619388
[TBL] [Abstract][Full Text] [Related]
17. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.
Sullivan PM; Mezdour H; Quarfordt SH; Maeda N
J Clin Invest; 1998 Jul; 102(1):130-5. PubMed ID: 9649566
[TBL] [Abstract][Full Text] [Related]
18. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
[TBL] [Abstract][Full Text] [Related]
20. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
